ISCO Stock Analysis
IS
Uncovered
International Stem Cell Corp is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
0.001
Dividend yield
—
Shares outstanding
8.004 B
International Stem Cell Corp. operates as a clinical stage biotechnology company. The company is headquartered in Carlsbad, California. The company went IPO on 2006-09-25. The firm's products are based on human cell culture and a type of pluripotent stem cells, human parthenogenetic stem cells (hpSCs). The firm is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of hpSCs for the treatment of various diseases of the central nervous system and liver diseases. The firm's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.